It is also contraindicated after a prior serious hypersensitivity reaction to semaglutide or any excipient, including anaphylaxis and angioedema
Phase 3 trials for retatrutide in obesity and type 2 diabetes are ongoing as of 2026, with results anticipated within the next 1218 months
Both are essential, both are limited, and both trend downward with age
Participants with obesity (body mass index (BMI) 30 kg/m) and moderate-to-severe KOA pain experienced significantly greater reductions in body weight and OA-related pain with weekly semaglutide injections compared to placebo [52]
To put this in perspective, this exceeds the results seen with any other approved weight loss medication currently available
[19] However, these effects result from gastric distension and increased fullness rather than hormonal changes in GLP-1 or other incretins